Drug drug interactions
Determining the potential for inhibition/induction of cytochrome P450 (CYP450) enzymes has become a major focus of regulatory agencies worldwide, due to the potential for these processes to produce serious adverse drug-drug interactions.
CDCO has developed and validated a range of in vitro reversible and time-dependent inhibition assays to assess the potential in vivo interactions with drug metabolising enzymes. Study designs are tailored to fit the stage of the discovery program.
Research platforms include:
- CYP450 inhibition using specific substrates in liver microsomes or recombinant CYP enzymes
- time-dependent inhibition/mechanism-based inhibition
- in vivo enzyme induction (rat/mouse)
- in vivo CYP inhibition (rat/mouse)
- in vivo interaction with concomitant therapy (rat/mouse)